| _ L'AQUILA pus AM G Bangone, G Corbellini, A Meldolesi, R Bassoli, C Castellano, G Regalzi, ... | | |
| " KJIHGFEDCBA Inhibition of Helicobacter pylori M Bugnoli, PF Bayeli, R Rappuoli European Journal of Gastroenterology & Hepatology 5, 683-685, 1993 | | 1993 |
| " Vaccines Against Meningococcus" An update of the progresses in meningitis prevention, based on the Meningococcus Scientific Exchange Meeting, Siena, Italy, 1-3 July 2008. M Frosch, R Moxon, WA Orenstein, R Rappuoli, GR Siber | | 2009 |
| [28] Selective immunotoxins prepared with mutant diphtheria toxins coupled to monoclonal antibodies M Colombatti, L Dell'Arciprete, R Rappuoli, G Tridente Methods in enzymology 178, 404-422, 1989 | 6 | 1989 |
| 15. PROTEIN ENGINEERING IN VACCINE DEVELOPMENT G GRANDI, MG PIZZA, E SCARLATO, R RAPPUOLI Protein Engineering For Industrial Biotechnology, 267, 2000 | | 2000 |
| 1885, the first rabies vaccination in humans R Rappuoli Proceedings of the National Academy of Sciences 111 (34), 12273-12273, 2014 | 32 | 2014 |
| 2. How is the economic assessment of vaccines performed today? B Standaert, R Rappuoli Journal of Market Access & Health Policy 5 (1), 1335163, 2017 | 37* | 2017 |
| 245 Vaccine Discovery and Translation of New Vaccine Technology R Rappuoli, J Telford, R Rosini, M Moschioni Post-genomic Approaches in Drug and Vaccine Development, 245-275, 2015 | | 2015 |
| 2D NMR Analysis as a Sensitive Tool for Evaluating the Higher-Order Structural Integrity of Monoclonal Antibody against COVID-19 F Cantini, E Andreano, I Paciello, V Ghini, F Berti, R Rappuoli, L Banci Pharmaceutics 14 (10), 1981, 2022 | 4 | 2022 |
| 3.5 Genetic Detoxification of Bacterial Toxins R Rappuoli, M Pizza Concepts in Vaccine Development, 361, 2012 | | 2012 |
| 3D imaging of the 58 kDa cell binding subunit of the Helicobacter pylori cytotoxin JM Reyrat, S Lanzavecchia, P Lupetti, M de Bernard, C Pagliaccia, ... Journal of molecular biology 290 (2), 459-470, 1999 | 119 | 1999 |
| 4. Specific Vaccination Strategies 4.1 Helicobacter pylori: Pathogenic Determinants and Strategies for Vaccine Design P Ghiara, A Covacci, JL Telford, R Rappuoli | | |
| 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents A Biolchi, S Tomei, B Brunelli, M Giuliani, S Bambini, R Borrow, H Claus, ... Infectious Diseases and Therapy 10, 307-316, 2021 | 21 | 2021 |
| 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp D Veggi, F Bianchi, L Santini, P Lo Surdo, CC Chesterman, W Pansegrau, ... PLoS Pathogens 16 (10), e1008882, 2020 | 7 | 2020 |
| 6 D| SEASE STATES AND VACCINES: SELECTED CASES V MASIGNANI, M PIZZA, R RAPPUOLI The Vaccine Book, 333, 2002 | | 2002 |
| 647 Lipidomics: a new window to biomedical frontiers 653 The challenges of regulating stem cell-based products PR Dormitzer, JB Ulmer, R Rappuoli, H Fukuda, S Hama, S Tamalampudi, ... | | |
| 7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains A Biolchi, S Tomei, L Santini, R La Gaetana, E Mori, P Novy, R Rappuoli, ... Open Forum Infectious Diseases 7 (Suppl 1), S26, 2020 | | 2020 |
| 7.6 Molecular Genetics of Bordetella Pertussis Virulence V Scarlato, D Beier, R Rappuoli Methods in Microbiology 27, 395-406, 1998 | 4 | 1998 |
| 85kDa neisserial antigen MM Giuliani, M Pizza, R Rappuoli, J Holst US Patent 7,700,119, 2010 | 4 | 2010 |
| A ‘tailor made’vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand J Holst, IS Aaberge, P Oster, D Lennon, D Martin, J O'Hallahan, K Nord, ... Weekly releases (1997–2007) 7 (30), 2262, 2003 | 28 | 2003 |
Mariagrazia PizzaGSK Vaccines - Imperial College在 imperial.ac.uk 的电子邮件经过验证
